Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma
Kamlesh Bisht, Taro Fukao, Marielle Chiron, et al.
Cancer Medicine (2023) Vol. 12, Iss. 20, pp. 20332-20352
Open Access | Times Cited: 18

Showing 18 citing articles:

Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature
Emiliano Barbieri, Enrica Antonia Martino, Elena Rivolti, et al.
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 5, pp. 365-381
Closed Access | Times Cited: 5
Efficacy and safety of anti-CD38 monoclonal antibodies-based therapy versus standard therapy in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis
Muhammad Osama, Muhammad Haris Khan, Sharib Raza Khan, et al.
Therapeutic Advances in Hematology (2025) Vol. 16
Open Access
Monoclonal anti-CD38 therapy in human myeloma: retrospects and prospects
Alberto L. Horenstein, Angelo Corso Faini, Fabio Morandi, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Overview of 1q abnormalities in multiple myeloma: scientific opinions from Italian experts
Mattia D’Agostino, Marina Martello, Lorenzo De Paoli, et al.
Annals of Hematology (2025)
Open Access
A review of antibody-based immunotherapy clinical trials for adult acute myeloid leukemia (AML): monoclonal antibodies (mAbs) and beyond
Kaitlyn C Dykes, Edward D. Ball
Expert Opinion on Biological Therapy (2025)
Closed Access
Exploring the depths of IgG4: insights into autoimmunity and novel treatments
Selen Ünlü, Blanca G. Sánchez Navarro, Elif Çakan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Preclinical characterization of a novel investigational monoclonal antibody CM313 with potent CD38-positive cell killing activity
Wei Liu, Juntao Yu, Kaiwen Sun, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Novel Heteroaryl Compounds as CD73 Inhibitors for Treating Cancer
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 6, pp. 775-776
Open Access | Times Cited: 2
Diagnosis of light‑chain deposition disease after renal transplantation: A case report and literature review
Jing Yue, Fang Xu, Ya Zhang, et al.
Experimental and Therapeutic Medicine (2024) Vol. 28, Iss. 3
Open Access | Times Cited: 1
A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma
Stefan Knop, Monika Szarejko, Norbert Grząśko, et al.
eJHaem (2024) Vol. 5, Iss. 5, pp. 940-950
Open Access | Times Cited: 1
Association of Blood NK Cell Phenotype with the Severity of Liver Fibrosis in Patients with Chronic Viral Hepatitis C with Genotype 1 or 3
В. В. Цуканов, А. А. Савченко, M. A. Cherepnin, et al.
Diagnostics (2024) Vol. 14, Iss. 5, pp. 472-472
Open Access
Novel CD73 Inhibitors for Treating Cancer
Ram W. Sabnis
ACS Medicinal Chemistry Letters (2024) Vol. 15, Iss. 5, pp. 571-572
Closed Access
Immune and Microbial Signatures Associated with PD-1 Blockade Sensitivity in a Preclinical Model for HPV+ Oropharyngeal Cancer
Jennifer Díaz-Rivera, Michael A. Rodríguez-Rivera, Natalie M. Meléndez-Vázquez, et al.
Cancers (2024) Vol. 16, Iss. 11, pp. 2065-2065
Open Access
Targeting CD38 with monoclonal antibodies disrupts key survival pathways in paediatric Burkitt's lymphoma malignant B cells
Kathrin Kläsener, Nadja Herrmann, Liliana Håversen, et al.
Clinical & Translational Immunology (2024) Vol. 13, Iss. 10
Open Access
Multiple myeloma and the potential of new checkpoint inhibitors for immunotherapy
Alí N. Kamali, Haleh Hamedifar, Michael Eisenhut, et al.
Therapeutic Advances in Vaccines and Immunotherapy (2024) Vol. 12
Open Access
Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy
Bingjie Fu, Rui Liu, Gongzhizi Gao, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Natural killer cell biology and therapy in multiple myeloma: challenges and opportunities
Kamlesh Bisht, Aimee Merino, Rob Igarashi, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access
Enhancing complement activation by therapeutic anti-tumor antibodies: Mechanisms, strategies, and engineering approaches
Vitalijs Ovcinnikovs, Karin Dijkman, Gijs G. Zom, et al.
Seminars in Immunology (2024) Vol. 77, pp. 101922-101922
Open Access
Page 1

Scroll to top